Showing 5081-5090 of 6036 results for "".
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- Kodiak Sciences Completes Enrollment of Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet AMDhttps://modernod.com/news/kodiak-sciences-completes-enrollment-of-phase-2b-3-pivotal-study-of-ksi-301-in-patients-with-wet-amd/2478561/Kodiak Sciences announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with wet age-related macular degeneration (AMD). DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enr
- Adverum Biotechnologies Announces Positive Interim Data From OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2478553/Adverum Biotechnologies announced positive new interim data from Cohorts 1-4 of the OPTIC phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). “With these impre
- Moderna Says mRNA COVID-19 Vaccine 94.5% Effectivehttps://modernod.com/news/moderna-says-mrna-covid-19-vaccine-94-5-effective/2478555/Moderna announced Monday that in the first interim analysis of the phase 3 COVE study, its experimental COVID-19 vaccine mRNA-1273 demonstrated efficacy of 94.5%. The company noted that the analysis was based on 95 cases of coronavirus infection, of which 90 cases were observed in the placebo gro
- Rural Hospitals Struggle to Find Places to Transfer Patients Amid COVID-19 Surgeshttps://modernod.com/news/rural-hospitals-struggle-to-find-places-to-transfer-patients-amid-covid-19-surges/2478551/Norton County Hospital is facing a major problem in recent days: Figuring out where to send patients that need a higher level of care. As larger hospitals become overwhelmed with serious cases of COVID-19, the options are dwindling. For Norton, the closest hospital that it has been able to
- Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy at AAO 2020 Virtualhttps://modernod.com/news/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-at-aao-2020-virtual/2478547/Apellis Pharmaceuticals announced findings from a large retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry was conducted in partnership wit
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-
- Nanoscope Therapeutics Announces Presentation at the 2020 AAOhttps://modernod.com/news/nanoscope-therapeutics-announces-presentation-at-the-2020-aao/2478545/Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy
- EyeMD EMR 2.0 All-in-One Platform Unveiled at AAO Virtualhttps://modernod.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/EyeMD EMR Healthcare Systems will debut EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system at the American Academy of Ophthalmology (AAO) Virtual Conference, taking place Nov. 13–15, 2020. EyeMD EMR 2.0 now includes EMR, PM and PACS functionality in one streamlined offering. EyeMD EMR P
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede